1. Home
  2. MAIA vs LEE Comparison

MAIA vs LEE Comparison

Compare MAIA & LEE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MAIA
  • LEE
  • Stock Information
  • Founded
  • MAIA 2018
  • LEE 1890
  • Country
  • MAIA United States
  • LEE United States
  • Employees
  • MAIA N/A
  • LEE N/A
  • Industry
  • MAIA Biotechnology: Pharmaceutical Preparations
  • LEE Newspapers/Magazines
  • Sector
  • MAIA Health Care
  • LEE Consumer Discretionary
  • Exchange
  • MAIA Nasdaq
  • LEE Nasdaq
  • Market Cap
  • MAIA 46.7M
  • LEE 39.6M
  • IPO Year
  • MAIA 2022
  • LEE N/A
  • Fundamental
  • Price
  • MAIA $1.88
  • LEE $6.80
  • Analyst Decision
  • MAIA
  • LEE
  • Analyst Count
  • MAIA 0
  • LEE 0
  • Target Price
  • MAIA N/A
  • LEE N/A
  • AVG Volume (30 Days)
  • MAIA 529.1K
  • LEE 33.9K
  • Earning Date
  • MAIA 08-08-2025
  • LEE 07-31-2025
  • Dividend Yield
  • MAIA N/A
  • LEE N/A
  • EPS Growth
  • MAIA N/A
  • LEE N/A
  • EPS
  • MAIA N/A
  • LEE N/A
  • Revenue
  • MAIA N/A
  • LEE $591,094,000.00
  • Revenue This Year
  • MAIA N/A
  • LEE N/A
  • Revenue Next Year
  • MAIA N/A
  • LEE N/A
  • P/E Ratio
  • MAIA N/A
  • LEE N/A
  • Revenue Growth
  • MAIA N/A
  • LEE N/A
  • 52 Week Low
  • MAIA $1.40
  • LEE $5.83
  • 52 Week High
  • MAIA $4.24
  • LEE $19.63
  • Technical
  • Relative Strength Index (RSI)
  • MAIA 56.41
  • LEE 54.12
  • Support Level
  • MAIA $1.80
  • LEE $6.04
  • Resistance Level
  • MAIA $2.15
  • LEE $7.00
  • Average True Range (ATR)
  • MAIA 0.13
  • LEE 0.37
  • MACD
  • MAIA 0.02
  • LEE 0.08
  • Stochastic Oscillator
  • MAIA 60.00
  • LEE 82.91

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

About LEE Lee Enterprises Incorporated

Lee Enterprises Inc is a local news publication company in the United States. It is a digital-first subscription business providing local markets with valuable, high-quality, trusted, intensely local news, information, advertising, and marketing services. The product portfolio of the company includes digital subscription platforms, daily, weekly, and monthly newspapers, and niche products, all delivering original local news and information as well as national and international news. The products offer digital and print editions, and content and advertising are available in real-time through the websites and mobile apps.

Share on Social Networks: